Company Filing History:
Years Active: 2006
Title: Zoltán Penzes – Innovator in Vaccine Development
Introduction: Zoltán Penzes, based in Madrid, Spain, is a notable inventor recognized for his contributions in the field of vaccine formulation. With a single patent to his name, he has made significant strides in developing innovative solutions for infectious diseases, particularly through his work with recombinant defective viral genomes.
Latest Patents: Zoltán Penzes holds a patent for "Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines." This patent describes vectors that comprise a recombinant defective viral genome capable of expressing at least one antigen important for inducing systemic and secretory immune responses. Notably, these vectors are designed to provide protection against various infectious agents, emphasizing their potential use in vaccines for animal species such as pigs, dogs, and cats. The technology incorporates a viral genome with essential modifications and dependencies, allowing for enhanced vaccine formulation.
Career Highlights: Zoltán Penzes’s professional journey has been closely associated with Cyanamid Ibérica, S.A. Here, he has utilized his expertise in virology and immunology to further vaccine development. His dedication to scientific research, combined with his inventive skills, has elevated his standing in the research community.
Collaborations: Throughout his career, Zoltán has collaborated with esteemed colleagues, including Luis Enjuanes Sanchez and Juan Plana Duran. These collaborations underscore the importance of teamwork in research and innovation, enabling breakthroughs in vaccine technologies and infectious disease management.
Conclusion: Zoltán Penzes is a pioneering inventor whose work exemplifies the critical intersection of research and practical application in the field of vaccine development. His patent for recombinant defective viral genomes stands as a testament to his innovative spirit and dedication to advancing medical science for the benefit of animal health. As he continues his work with colleagues at Cyanamid Ibérica, his contributions will undoubtedly play a vital role in shaping the future of vaccines and infectious disease prevention.